[S1 Text](#pone.0156474.s001){ref-type="supplementary-material"}, [S1](#pone.0156474.s002){ref-type="supplementary-material"} and [S2](#pone.0156474.s003){ref-type="supplementary-material"} Tables are incorrect. Please view the corrected [S1 Text](#pone.0156474.s001){ref-type="supplementary-material"}, [S1](#pone.0156474.s002){ref-type="supplementary-material"} and [S2](#pone.0156474.s003){ref-type="supplementary-material"} Tables here.

Supporting Information {#sec001}
======================

###### Note on *APP*/*PS1* mice.

(PDF)

###### 

Click here for additional data file.

###### Solver run times and percent changes in final diseased neuron concentration and Aβ~42~ load.

Each percent change is given in absolute value when compared to results from a run solved with ode45 for a 90 day simulation of a nine month-old *APP*/*PS1* transgenic mouse with mg ⋅ kg^−1^ bexarotene treatment.

(PDF)

###### 

Click here for additional data file.

###### Percent change of the concentration of healthy brain cells in a 90 day simulation of nine-month-old *APP*/*PS1* mouse with 100 mg ⋅ kg^−1^ bexarotene treatment.

Parameters are increased by 10%, and the approximate corresponding percent change of the system is given for 0 mg ⋅ kg^−1^ and 100 mg ⋅ kg^−1^ of bexarotene.

(PDF)

###### 

Click here for additional data file.
